High Levels of Blood Hormones Raise Prostate Cancer Risk
By LabMedica International staff writers Posted on 11 Nov 2019 |

Image: Histopathology of prostate cancer: crystalloids (bright eosinophilic rhomboid to prismatic structures, seen in ~40% cancer) and amorphous eosinophilic secretions (Photo courtesy the American Urological Association).
Men with higher levels of 'free' testosterone and a growth hormone in their blood are more likely to be diagnosed with prostate cancer. Other factors such as older age, ethnicity and a family history of the disease are already known to increase a man's risk of developing prostate cancer.
Prostate cancer is one of the most common types of cancer in men. Usually prostate cancer grows slowly and is initially confined to the prostate gland, where it may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.
A team of scientists working with those at the University of Oxford (Oxford, UK) studied 200,452 men who are part of the UK Biobank project. All were free of cancer when they joined the study and were not taking any hormone therapy. The men gave blood samples that were tested for their levels of testosterone and a growth hormone called insulin-like growth factor-I (IGF-I). The team calculated levels of free testosterone, which is testosterone that is circulating in the blood and not bound to any other molecule and can therefore have an effect in the body. A subset of 9,000 of men gave a second blood sample at a later date, to help the investigators account for natural fluctuations in hormone levels. The men were followed for an average of six to seven years to see if they went on to develop prostate cancer. Within the group, there were 5,412 cases and 296 deaths from the disease.
The scientists reported that men with higher concentrations of the two hormones in their blood were more likely to be diagnosed with prostate cancer. For every increase 5 nmol/L of IGF-I, men were 9% more likely to develop prostate cancer. For every increase of 50 pmol/L, there was a 10% increase in prostate cancer risk. Looking at the population as a whole, the scientists say their findings correspond to a 25% greater risk in men who have the highest levels of IGF-I, compared to those with the lowest. Men with the highest 'free' testosterone levels face a 18% greater risk of prostate cancer, compared to those with the lowest levels.
Hashim Ahmed, MD, a Professor Urology at Imperial College London (London, UK), said, “These results are important because they show that there are at least some factors that influence prostate cancer risk that can potentially be altered. In the longer term, it could mean that we can give men better advice on how to take steps to reduce their own risk. This study also shows the importance of carrying out very large studies, which are only possible thanks to the thousands of men who agreed to take part.” The study was presented at the National Cancer Research Institute 2019 cancer conference held November 3 – November 5, 2019 in Glasgow, UK.
Related Links:
University of Oxford
Imperial College London
Prostate cancer is one of the most common types of cancer in men. Usually prostate cancer grows slowly and is initially confined to the prostate gland, where it may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.
A team of scientists working with those at the University of Oxford (Oxford, UK) studied 200,452 men who are part of the UK Biobank project. All were free of cancer when they joined the study and were not taking any hormone therapy. The men gave blood samples that were tested for their levels of testosterone and a growth hormone called insulin-like growth factor-I (IGF-I). The team calculated levels of free testosterone, which is testosterone that is circulating in the blood and not bound to any other molecule and can therefore have an effect in the body. A subset of 9,000 of men gave a second blood sample at a later date, to help the investigators account for natural fluctuations in hormone levels. The men were followed for an average of six to seven years to see if they went on to develop prostate cancer. Within the group, there were 5,412 cases and 296 deaths from the disease.
The scientists reported that men with higher concentrations of the two hormones in their blood were more likely to be diagnosed with prostate cancer. For every increase 5 nmol/L of IGF-I, men were 9% more likely to develop prostate cancer. For every increase of 50 pmol/L, there was a 10% increase in prostate cancer risk. Looking at the population as a whole, the scientists say their findings correspond to a 25% greater risk in men who have the highest levels of IGF-I, compared to those with the lowest. Men with the highest 'free' testosterone levels face a 18% greater risk of prostate cancer, compared to those with the lowest levels.
Hashim Ahmed, MD, a Professor Urology at Imperial College London (London, UK), said, “These results are important because they show that there are at least some factors that influence prostate cancer risk that can potentially be altered. In the longer term, it could mean that we can give men better advice on how to take steps to reduce their own risk. This study also shows the importance of carrying out very large studies, which are only possible thanks to the thousands of men who agreed to take part.” The study was presented at the National Cancer Research Institute 2019 cancer conference held November 3 – November 5, 2019 in Glasgow, UK.
Related Links:
University of Oxford
Imperial College London
Latest Pathology News
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
Channels
Molecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more